Modafinil for Parkinson's disease fatigue.

Fatigue is common in Parkinson's disease (PD), occurring in up to 42% of patients (2). There is no recognized treatment. This is a study of modafinil for Parkinson's disease related fatigue.

Pathological gambling in Parkinson's disease.

Patients often are in substantial debt before the problem is recognised

A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.

Objectives: Apomorphine is a potent dopamine agonist useful in the treatment of Parkinson's disease patients with disabling motor fluctuations and 'off' periods, not responding to oral medication. It can also be of benefit in reducing dyskinesia by providing more constant dopaminergic stimulation and permitting lower levodopa dosage. However, there is a paucity of information on long-term benefits of apomorphine, including no large-scale phase III trial.